LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Digital Pathology Solution Provides Truly Interoperable Platform to Streamline Workflow

By LabMedica International staff writers
Posted on 11 Oct 2022

Gestalt Diagnostics, Inc. (Spokane, WA, USA) has received CE-IVD marks for two of the main components of PathFlow. Both the PathFlow viewer and the proprietary, automated workflows now have European regulatory clearance for broad use in clinical, education, and research laboratories. Gestalt's PathFlow is a universal, easy-to-use digital platform for pathology laboratories that enables pathologists to interpret, and diagnose patient cases quickly, efficiently, and in a fully automated fashion. Gestalt provides the enterprise solutions, and services, to transform anatomic pathology laboratories from glass slides, microscopes, and couriers to a fully interoperable, automated, electronic digital workflow.

The European regulatory certification of the key components of Gestalt's PathFlow provides the support some healthcare facilities need to fully deploy and recognize the value of digital pathology throughout their organizations. Gestalt's feature-rich viewer is consistent throughout all the PathFlow modules whether clinical, education, or research and provides the pathologist or scientist with access to all of the information related to their case, study, or course in a single, streamlined environment.


Image: PathFlow Viewer and Automated Workflow are now European regulatory cleared for use in primary diagnosis (Photo courtesy of Gestalt)
Image: PathFlow Viewer and Automated Workflow are now European regulatory cleared for use in primary diagnosis (Photo courtesy of Gestalt)

"A truly interoperable platform which incorporates every component necessary to streamline the workflow for pathologists is essential for leveraging the full benefits of digital pathology," said Lisa-Jean Clifford, COO & Chief Strategy Officer at Gestalt. "The receipt of these CE-IVD marks is an important milestone for our company in providing the assurance that our solutions meet the regulatory standards required for patient care while increasing speed and efficiency for their providers."

Related Links:
Gestalt Diagnostics, Inc. 


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit

Latest Pathology News

AI-Based Model Predicts Kidney Cancer Therapy Response
11 Oct 2022  |   Pathology

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
11 Oct 2022  |   Pathology

World’s First AI Model for Thyroid Cancer Diagnosis Achieves Over 90% Accuracy
11 Oct 2022  |   Pathology